CN100364530C - 治疗慢性鼻炎的左旋咪唑 - Google Patents
治疗慢性鼻炎的左旋咪唑 Download PDFInfo
- Publication number
- CN100364530C CN100364530C CNB2003101003780A CN200310100378A CN100364530C CN 100364530 C CN100364530 C CN 100364530C CN B2003101003780 A CNB2003101003780 A CN B2003101003780A CN 200310100378 A CN200310100378 A CN 200310100378A CN 100364530 C CN100364530 C CN 100364530C
- Authority
- CN
- China
- Prior art keywords
- nasal
- rhinitis
- levamisole
- chronic
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 61
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 title claims abstract description 45
- 229960001614 levamisole Drugs 0.000 title claims abstract description 45
- 201000009151 chronic rhinitis Diseases 0.000 title claims abstract description 35
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000007921 spray Substances 0.000 claims abstract description 18
- 239000007923 nasal drop Substances 0.000 claims abstract description 17
- 239000000443 aerosol Substances 0.000 claims abstract description 11
- 230000001684 chronic effect Effects 0.000 claims description 25
- 230000001969 hypertrophic effect Effects 0.000 claims description 11
- 229940098458 powder spray Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940100662 nasal drops Drugs 0.000 abstract 1
- 241000158526 Nasalis Species 0.000 description 24
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 20
- 206010028748 Nasal obstruction Diseases 0.000 description 17
- 210000003928 nasal cavity Anatomy 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 12
- 210000004877 mucosa Anatomy 0.000 description 11
- 210000002850 nasal mucosa Anatomy 0.000 description 11
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 10
- 229960002179 ephedrine Drugs 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 7
- 229940097572 chloromycetin Drugs 0.000 description 7
- 210000003097 mucus Anatomy 0.000 description 7
- 210000001944 turbinate Anatomy 0.000 description 7
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007922 nasal spray Substances 0.000 description 6
- 210000001331 nose Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 201000007100 Pharyngitis Diseases 0.000 description 5
- 206010039085 Rhinitis allergic Diseases 0.000 description 5
- 206010044302 Tracheitis Diseases 0.000 description 5
- 201000010105 allergic rhinitis Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000009423 ventilation Methods 0.000 description 5
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010061926 Purulence Diseases 0.000 description 4
- 239000003229 sclerosing agent Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010061876 Obstruction Diseases 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000492 nasalseptum Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000001705 Mouth breathing Diseases 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 238000002691 topical anesthesia Methods 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010001229 Adenoidal hypertrophy Diseases 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 206010009152 Chronic tonsillitis Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010067993 Mucosal necrosis Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010070488 Upper-airway cough syndrome Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000002817 coal dust Substances 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- GRIXGZQULWMCLU-UHFFFAOYSA-L disodium;7-[[2-carboxylato-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].C12OCC(CSC=3N(N=NN=3)C)=C(C([O-])=O)N2C(=O)C1(OC)NC(=O)C(C([O-])=O)C1=CC=C(O)C=C1 GRIXGZQULWMCLU-UHFFFAOYSA-L 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 230000010352 nasal breathing Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960000349 nitrofural Drugs 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960005491 sodium morrhuate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000009628 steelmaking Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101003780A CN100364530C (zh) | 2003-10-14 | 2003-10-14 | 治疗慢性鼻炎的左旋咪唑 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101003780A CN100364530C (zh) | 2003-10-14 | 2003-10-14 | 治疗慢性鼻炎的左旋咪唑 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1606980A CN1606980A (zh) | 2005-04-20 |
| CN100364530C true CN100364530C (zh) | 2008-01-30 |
Family
ID=34755935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101003780A Expired - Fee Related CN100364530C (zh) | 2003-10-14 | 2003-10-14 | 治疗慢性鼻炎的左旋咪唑 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100364530C (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008028324A1 (fr) * | 2006-08-28 | 2008-03-13 | Jiangsu Simcere Pharmaceutical R & D Co., Ltd | Nouvelle préparation de lévamisole pour traiter une rhinite allergique |
| CN106974919A (zh) * | 2017-01-02 | 2017-07-25 | 胡友忠 | 综合性疾病系统化治疗药物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4287176A (en) * | 1980-10-09 | 1981-09-01 | American Cyanamid Co. | Anthelmintic levamisole and tetramisole gel compositions |
| US4439439A (en) * | 1981-03-24 | 1984-03-27 | Janssen Pharmaceutica N.V. | Non-irritating tetramisole- or levamisole pour-on conpositions |
| CN1375291A (zh) * | 2001-03-16 | 2002-10-23 | 王玉万 | 一种含左旋咪唑或其盐类的兽用复方注射剂 |
| CN1439369A (zh) * | 2002-02-22 | 2003-09-03 | 王鹤尧 | 治疗鼻息肉和鼻息肉病的左旋咪唑新剂型 |
-
2003
- 2003-10-14 CN CNB2003101003780A patent/CN100364530C/zh not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4287176A (en) * | 1980-10-09 | 1981-09-01 | American Cyanamid Co. | Anthelmintic levamisole and tetramisole gel compositions |
| US4439439A (en) * | 1981-03-24 | 1984-03-27 | Janssen Pharmaceutica N.V. | Non-irritating tetramisole- or levamisole pour-on conpositions |
| CN1375291A (zh) * | 2001-03-16 | 2002-10-23 | 王玉万 | 一种含左旋咪唑或其盐类的兽用复方注射剂 |
| CN1439369A (zh) * | 2002-02-22 | 2003-09-03 | 王鹤尧 | 治疗鼻息肉和鼻息肉病的左旋咪唑新剂型 |
Non-Patent Citations (3)
| Title |
|---|
| 左旋咪唑的临床新用途. 任可忠.中国乡村医生杂志,第3期. 1998 * |
| 甲硝哒唑和左旋咪唑治疗慢性鼻炎和慢性咽炎的疗效观察. 徐家喆等.锦州医学院学报,第6卷第3期. 1985 * |
| 盐酸左旋咪唑栓免疫调节作用的临床观察. 李向东等.天津药学,第12卷第2期. 2000 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1606980A (zh) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104352587B (zh) | 一种治疗鼻炎的软膏 | |
| CN106924378A (zh) | 一种防治和/或治疗慢性唇炎的中草药唇膏 | |
| CN103948732B (zh) | 一种治疗过敏性鼻炎的中药组合物 | |
| CN101224276B (zh) | 一种治疗鼻炎的中成药 | |
| CN103623267B (zh) | 一种治疗过敏性鼻炎的药物 | |
| CN101933963B (zh) | 一种治疗头痛的鼻用原位凝胶剂 | |
| CN108185509A (zh) | 一种用于治疗鼻炎的鼻烟制品 | |
| CN1606980A (zh) | 治疗慢性鼻炎的左旋咪唑新剂型 | |
| CN100446765C (zh) | 治疗慢性鼻炎的阿苯达唑新剂型 | |
| CN103599274A (zh) | 一种治疗过敏性鼻炎的中药 | |
| CN103623065A (zh) | 一种治疗流行性感冒的药物组合物 | |
| CN110013502A (zh) | 一种防治急慢性鼻炎、鼻窦炎的组合物 | |
| CN1748677A (zh) | 治疗慢性鼻炎的甲苯咪唑新剂型 | |
| CN102716165A (zh) | 治疗鼻炎的中草药 | |
| CN101181592B (zh) | 治疗顽固性头痛、偏头痛的中药 | |
| CN1748687A (zh) | 治疗慢性鼻炎的奥苯达唑新剂型 | |
| CN1748692A (zh) | 治疗慢性鼻炎的阿苯达唑鼻腔凝胶剂 | |
| CN1748682A (zh) | 治疗慢性鼻炎的奥苯达唑鼻腔凝胶剂 | |
| CN108403863A (zh) | 一种治疗鼻炎的鼻速康制剂 | |
| CN104547128A (zh) | 治疗鼻炎的药物 | |
| CN102940882B (zh) | 一种治疗呼吸道疾病的药物 | |
| CN1751686A (zh) | 治疗慢性鼻炎的阿司咪唑新剂型 | |
| CN103463236B (zh) | 一种药物组合物及其制备方法 | |
| CN104524297A (zh) | 一种治疗肾阳不足型变应性鼻炎的中药 | |
| CN102198201B (zh) | 一种治疗虚寒性头疼的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU SIMECERE MEDICINE RESEARCH CO., LTD. Free format text: FORMER OWNER: ZHENG WENJIE; APPLICANT Effective date: 20070216 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070216 Address after: 210042 No. 12, Nanjing, Huayuan Road Applicant after: Jiangsu Simcere Pharmaceutical Research Company Limited Address before: 100089, Beijing, Kunming, Hunan Road, Haidian District century 62, Yuanda Park, No. 6, zone 6, building 5C Applicant before: Zheng Wenjie Co-applicant before: Wang Heyao |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080130 Termination date: 20101014 |